Tech Company Financing Transactions

ReCode Therapeutics Funding Round

ReCode Therapeutics, based in Menlo Park, secured $120 million from Leaps by Bayer, Matrix Capital Management and Amgen Ventures.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

1455 Adams Dr.
Menlo Park, CA 94025
USA

Phone

469-306-1618

Website

www.recodetx.com

Email Address

[email protected]

Overview

ReCode Therapeutics is a biopharmaceutical company developing precision medicines for pulmonary diseases with significant unmet medical need. ReCode's diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF).

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

David Lockhart

        

Browse more venture capital transactions:

Prev: 6/29/2022: Kukua venture capital transaction
Next: 6/29/2022: Nautical Commerce venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary